Global Market for Biomarker-Based Infectious Disease Tests to Surpass USD 20 Billion in 2027
|
By HospiMedica International staff writers Posted on 22 May 2023 |
|
Biomarkers encompass over a thousand substances utilized as reagents, consumables, and/or test components for a variety of diagnostics and medical research procedures. They also include substances that can detect and measure genetic alterations in patient samples. Biomarkers for infectious diseases include proteins (antigens), antibodies generated due to the presence of infectious agents, and genetic markers. Recent advancements like mass spectrometry are being employed for pathogen identification. The global market for infectious disease tests that utilize biomarkers is anticipated to expand at a compound annual growth rate (CAGR) of 5.8% from USD 14.8 billion in 2021 to USD 20.7 billion in 2027, fueled by factors such as an aging population with higher disease vulnerability, an increase in targeted therapies, and a large and expanding clinical diagnostic test market.
These are the latest findings of Kalorama Information (Arlington, VA, USA), a leading publisher of market research in medical markets.
Laboratory immunoassays are expected to account for more than 60% of global infectious disease biomarker sales over the long term. This can be attributed to the technology’s ability in detecting a wide range of common pathogens, including antigens or antibodies associated with pneumonia, influenza, Clostridium difficile (C. diff), hepatitis C, HIV, herpes simplex virus (HSV), and Lyme disease. Enzyme-linked immunoassays are especially suitable for diagnosing these diseases. In the case of more complex infectious disease testing applications, polymerase chain reaction (PCR), microarrays, and other molecular technologies are likely to garner a higher share of the global value and volume. These technologies are capable of identifying DNA, RNA, and genes associated with pathogens, enabling a much more definitive diagnosis.
Molecular tests can identify infectious agents such as HPV, Chlamydia trachomatis/Neisseria gonorrhea (CT/NG), and tuberculosis. Moreover, these tests are increasingly being used to detect genes associated with resistance to healthcare-related infections and disease-resistant pathogens. Rapid immunoassays employing lateral flow immunochromatographic techniques are being developed to allow detection of an increasing array of infectious diseases at point-of-care locations, including clinics, doctors' offices, hospital emergency rooms, and patient homes. Specific tests now available in this area include ones for bacterial vaginosis (BV), chlamydia, dengue, Ebola, HIV, influenza, Legionnaires' disease, malaria, rotavirus, respiratory syncytial virus (RSV), group A Streptococcus, Treponema pallidum, and Trichomonas vaginalis. The sources for specimens for rapid immunoassays encompass a wide variety of substances, such as whole blood, serum, urine, nasal and throat swabs, stool samples, and vaginal swabs.
Related Links:
Kalorama Information
Latest Point of Care News
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more
Critical Care
view channel
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
Pulmonary hypertension is a progressive, life‑threatening disease that is frequently missed early because symptoms such as dyspnea are nonspecific and diagnostic delays can exceed two years.... Read more
Surgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
